nihonkohden

Philosophy & Strategy

Top Message

Left: Hirokazu Ogino,  President and CEO Right: Takashi Tamura,  Representative Director, Exective Operating Officer Left: Hirokazu Ogino, Representative Director, President and CEO
Right: Takashi Tamura, Representative Director, Exective Operating Officer

First, we would like to sincerely thank our shareholders for your continued support.

We hereby report the results for the first half of FY2020 ending March 31, 2021.

In the first half of FY2019, the COVID-19 pandemic adversely affected national healthcare systems in every country. In order to fulfill our social responsibility as a medical device manufacturer, the Company focused on implementing infection prevention measures to ensure business continuity as well as ramping up production to address the global supply shortage of medical devices.

In Japan, Nihon Kohden concentrated on enhancing sales activities which match each market. The Company also focused on selling in-house products as well as strengthening its marketing and service capabilities, creating customer value which contributed to improving medical safety, patient outcomes, and operating efficiency. However, sales in all markets decreased not only because there was a reactionary decline from the last-minute surge in demand in the first half of FY2019, preceding consumption tax increase, but also because medical institutions reduced the number of testing and surgical procedures, and postponed or froze the purchase budget for certain products such as Physiological Measuring Equipment. Internationally, sales in all regions achieved double-digit growth because demand for patient monitors and ventilators surged due to the growing number of COVID-19 patients. As a result, overall sales decreased over the first half of FY2019, but operating income increased favorably. The Company revised its forecast for FY2020 because the first half result exceeded the Company’s initial estimates, while the Company continues to see uncertainty related to the impact from resurgence of COVID-19.

Nihon Kohden announced a long-term vision, BEACON 2030, for the next ten years to 2030, in September 2020. The Company aims to create a better future for people and healthcare by solving global medical issues. 

The interim dividend for the first half of FY2020 was 17 yen per share. We deeply appreciate your continued support.